-
公开(公告)号：US20240150364A1
公开(公告)日：2024-05-09
申请号：US18507678
申请日：2023-11-13
Applicant: Genentech, Inc.
Inventor： Paul Gibbons , Emily Hanan , Wendy Liu , Joseph Lyssikatos , Steven R. Magnuson , Rohan Mendonca , Richard Pastor , Thomas E. Rawson , Michael Siu , Mark E. Zak , Aihe Zhou , Bing-Yan Zhu , Christopher Hurley
IPC: C07D487/04 , A61K31/519 , A61P17/06 , A61P29/00 , A61P35/02
CPC classification number: C07D487/04 , A61K31/519 , A61P17/06 , A61P29/00 , A61P35/02
Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
-
公开(公告)号：US10597383B2
公开(公告)日：2020-03-24
申请号：US16250230
申请日：2019-01-17
Applicant: Genentech, Inc.
Inventor： Vishal Verma , Daniel Shore , Matthew Volgraf , Anthony A. Estrada , Joseph Lyssikatos
IPC: C07D401/14 , C07D401/12 , C07D403/12 , C07D403/14 , C07D405/14
Abstract: The invention is concerned with the compounds of formula I: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
-
公开(公告)号：US10010549B2
公开(公告)日：2018-07-03
申请号：US14927267
申请日：2015-10-29
Applicant: Genentech, Inc.
Inventor： Anthony Estrada , Liting Dong , Kevin X. Chen , Paul Gibbons , Malcolm Huestis , Terry Kellar , Wen Liu , Changyou Ma , Joseph Lyssikatos , Alan Olivero , Snahel Patel , Daniel Shore , Michael Siu
IPC: A61K31/506 , A61K31/4545 , A61K31/5377 , A61K31/55 , A61K35/30 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/18 , C07D487/08 , C07D491/08 , C07D495/08 , C07D519/00 , C07D471/08 , A61K45/06 , A61K31/5386 , A61K31/553 , C07D417/14 , C07D487/14 , C07D487/18 , A61K31/444
CPC classification number: A61K31/506 , A61K31/444 , A61K31/4545 , A61K31/5377 , A61K31/5386 , A61K31/55 , A61K31/553 , A61K35/30 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D471/18 , C07D487/08 , C07D487/14 , C07D487/18 , C07D491/08 , C07D495/08 , C07D519/00 , A61K2300/00
Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
-
公开(公告)号：US09216980B2
公开(公告)日：2015-12-22
申请号：US14255898
申请日：2014-04-17
Applicant: Genentech, Inc.
Inventor： Huifen Chen , Hazel Joan Dyke , Charles Ellwood , Emanuela Gancia , Lewis J. Gazzard , Simon Goodacre , Samuel Kintz , Joseph Lyssikatos , Calum MacLeod , Karen Williams
IPC: A61K31/437 , A61K31/496 , C07D471/14 , A61K31/4375 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D491/107 , C07D495/04 , C07D513/04 , A61K31/55 , A61K31/553 , C07D519/00
CPC classification number: C07D471/14 , A61K31/4375 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , C07D491/107 , C07D495/04 , C07D513/04 , C07D519/00
Abstract: Methods of use of compounds of formula (I) for treating cancer: wherein X, Y, X, R3, R5 and R6 are as defined herein.
Abstract translation: 式（I）化合物用于治疗癌症的方法：其中X，Y，X，R 3，R 5和R 6如本文所定义。
-
公开(公告)号：USRE47848E1
公开(公告)日：2020-02-11
申请号：US15902746
申请日：2018-02-22
Applicant: Genentech, Inc.
Inventor： Anthony Estrada , Alan G. Olivero , Snahel Patel , Michael Siu , Joseph Lyssikatos , Malcolm Huestis , Terry Kellar
IPC: A61K31/55 , C07D403/14 , A61K35/30 , C07D491/08 , C07D495/08 , C07D519/00 , C07D471/08 , A61K45/06 , A61K31/5386 , C07D487/08 , C07D413/14 , C07D471/18 , C07D405/14 , C07D403/04 , C07D401/14 , A61K31/5377 , A61K31/506 , A61K31/4545 , A61K31/444 , A61K31/553 , A61K31/155
Abstract: The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula all have the meaning as defined herein.
-
Patent Agency Ranking
公开(公告)号：US20180133219A1
公开(公告)日：2018-05-17
申请号：US15868301
申请日：2018-01-11
Applicant: Genentech, Inc.
Inventor： Anthony Estrada , Liting Dong , Kevin X. Chen , Paul Gibbons , Malcolm Huestis , Terry Kellar , Wen Liu , Changyou Ma , Joseph Lyssikatos , Alan Olivero , Snahel Patel , Daniel Shore , Michael Siu
IPC: A61K31/506 , A61K31/444 , A61K35/30 , C07D487/14 , A61K31/553 , C07D417/14 , C07D487/18 , A61K31/55 , C07D401/14 , A61K31/5377 , C07D495/08 , A61K31/4545 , C07D519/00 , A61K31/5386 , A61K45/06 , C07D471/08 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/18 , C07D487/08 , C07D491/08
CPC classification number: A61K31/506 , A61K31/444 , A61K31/4545 , A61K31/5377 , A61K31/5386 , A61K31/55 , A61K31/553 , A61K35/30 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D471/18 , C07D487/08 , C07D487/14 , C07D487/18 , C07D491/08 , C07D495/08 , C07D519/00 , A61K2300/00
Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
-
公开(公告)号：US09212186B2
公开(公告)日：2015-12-15
申请号：US14531349
申请日：2014-11-03
Applicant: Genentech, Inc.
Inventor： Charles Baker-Glenn , Bryan K. Chan , Jennafer Dotson , Anthony Estrada , Timothy Heffron , Joseph Lyssikatos , Zachary Sweeney
IPC: A61K31/506 , C07D487/04 , C07D471/04 , C07D498/04 , C07D498/20 , C07D491/04 , C07D403/12 , C07D491/048
CPC classification number: C07D487/04 , A61K31/506 , C07D403/12 , C07D471/04 , C07D491/04 , C07D491/048 , C07D498/04 , C07D498/20
Abstract: Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3 and A are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
Abstract translation: 式I化合物或其药学上可接受的盐，其中X，R 1，R 2，R 3和A如本文所定义。 还公开了制备化合物和使用该化合物治疗与LRRK2受体（例如帕金森病）相关的疾病的方法。
-
公开(公告)号：US10028954B2
公开(公告)日：2018-07-24
申请号：US15041375
申请日：2016-02-11
Applicant: Genentech, Inc.
Inventor： Anthony Estrada , Alan G Olivero , Snahel Patel , Michael Siu , Joseph Lyssikatos
IPC: A61K31/506 , A61K31/55 , A61K31/5377 , A61K31/444
CPC classification number: A61K31/506 , A61K31/444 , A61K31/4545 , A61K31/5377 , A61K31/5386 , A61K31/55 , A61K31/553 , A61K35/30 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D471/18 , C07D487/08 , C07D487/14 , C07D487/18 , C07D491/08 , C07D495/08 , C07D519/00 , A61K2300/00
Abstract: The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula all have the meaning as defined herein.
-
公开(公告)号：US20170239246A9
公开(公告)日：2017-08-24
申请号：US15041375
申请日：2016-02-11
Applicant: Genentech, Inc.
Inventor： Anthony O. Estrada , Alan G Olivero , Snahel Patel , Michael Siu , Joseph Lyssikatos
IPC: A61K31/506 , A61K31/444 , A61K31/5377 , A61K31/55
CPC classification number: A61K31/506 , A61K31/444 , A61K31/4545 , A61K31/5377 , A61K31/5386 , A61K31/55 , A61K31/553 , A61K35/30 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D471/18 , C07D487/08 , C07D487/14 , C07D487/18 , C07D491/08 , C07D495/08 , C07D519/00 , A61K2300/00
Abstract: The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula all have the meaning as defined herein.
-
公开(公告)号：US20150051201A1
公开(公告)日：2015-02-19
申请号：US14531349
申请日：2014-11-03
Applicant: Genentech, Inc.
Inventor： Charles Baker-Glenn , Bryan K. Chan , Jennafer Dotson , Anthony Estrada , Timothy Heffron , Joseph Lyssikatos , Zachary Sweeney
IPC: C07D487/04 , C07D498/04 , C07D498/20 , C07D471/04
CPC classification number: C07D487/04 , A61K31/506 , C07D403/12 , C07D471/04 , C07D491/04 , C07D491/048 , C07D498/04 , C07D498/20
Abstract: Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3 and A are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
Abstract translation: 式I化合物或其药学上可接受的盐，其中X，R 1，R 2，R 3和A如本文所定义。 还公开了制备化合物和使用该化合物治疗与LRRK2受体（例如帕金森病）相关的疾病的方法。
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.032 seconds)
